Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed Mar 26, 2025 · 10-K · 85 days after period end · 0001799191-25-000014
| Metric | Q4 2024 | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $100.27M | $85.79M | $71.42M | $52.30M |
| Net Income | -$13.18M | -$18.75M | -$11.01M | -$10.06M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Mar 26, 2025 · 85 d after period end
